Physician profile
Janice J Richardson
NPI 1073127841
$9,247.99
in general payments reported to CMS, 2019-2025
17 companies · $3,404 in 2025
The $3,404 reported for 2025 was more than what 99% of Home Health (Registered Nurse) providers received nationally (typical 2025 total: $34.85).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $433 · 2023: $2,918 · 2024: $2,492 · 2025: $3,404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,739 · Education: $76.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,738.67 |
| Education | $76.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,767.26 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,223.07 | 2022-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $1,059.19 | 2023-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $894.10 | 2022-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $807.13 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $773.86 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $678.13 | 2022-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $586.01 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $390.74 | 2024-2025 | Qelbree |
| Axsome Therapeutics, INC. | $346.06 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $325.90 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $99.98 | 2022-2023 | Trintellix |
| Sunovion Pharmaceuticals INC. | $93.71 | 2022 | |
| Almatica Pharma LLC | $83.40 | 2025 | Loreev Xr |
| Tris Pharma INC | $53.53 | 2025 | Dyanavel Xr |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $36.47 | 2025 | Xelstrym |
| Janssen Pharmaceuticals, INC | $29.45 | 2023 | Invega Trinza, Invega Sustenna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janice Richardson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.